|
|
CSL demonstrates robust immune response from single (15mcg) dose of monovalent pandemic (H1N1) 2009 influenza A vaccine in healthy adults
CSL demonstrates robust immune response from single (15mcg) dose of monovalent pandemic (H1N1) 2009 influenza A vaccine in healthy adults
Melbourne, Australia — 11/09/2009
CSL Limited, Australia’s leading biopharmaceutical company, announced today that preliminary data from the first study of its candidate pandemic H1N1 vaccine demonstrated a robust immune response in healthy adults after a single unadjuvanted15mcg dose.
The preliminary data, published today as an original article in the
New England Journal of Medicine , showed that over 95% of participants receiving the single 15mcg dose of the vaccine achieved antibody levels that correlate with the prevention of influenza infection.1
The study also shows that the vaccine has a tolerability profile consistent with seasonal influenza vaccines.
Download the Release:
 CSL demonstrates robust immune response from single (15mcg) dose of monovalent pandemic (H1N1) 2009 influenza A vaccine in healthy adults (0.05Mb)
Media Contacts: Dr Rachel David - Australia and ROW
Director of Public Affairs
CSL Limited
Phone: 613 9389 1821 Mobile: 0401 775 779
Email: rachel.david@csl.com.au
|
| Dr Daniella Goldberg - Australia and ROW
Mobile: 0416 211 067
Email: daniella@ogilvyprhealth.com
| | Sheila Burke - USA
Director - Public Relations & Communications
CSL Biotherapies US
Mobile: 1 484 919 2618 Office: 1 610 878 4209
Email: sheila.burke@cslbehring.com
| |
1 de Jong J C Haemaggutination -Inhibiting Antibody to Influenza Virus. Dev Biol 2003 vol 115, 63-73.
|